OpenAI OpCo LLC

Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of drug targets, continuing the biotech’s rapid embrace of AI in drug discovery and development. Delaware-based Incyte partnered with Genesis in February 2025. That deal, which included a $30 million upfront payment, positioned the companies to collaborate on two targets and gave Incyte the option to nominate a third target for a predetermined fee. Genesis has now secured an expanded agreement after demonstrating how its AI platform can discover and optimize small molecules against complex targets. Under the expanded agreement, the partners will work on at least five new targets selected by Incyte. The deal also gives the biotech the option to nominate additional collaboration targets over time. In return, Incyte has paid the upfront fee and made a $40 million equity investment in Genesis. The agreement includes up to $232 million in milestones per program, bringing the potential value of the deal to more than $1 billion across the first five targets. Reaching that figure would require the partners to secure approvals across multiple indications and major markets while also hitting commercial sales milestones. If Incyte adds more targets, the deal’s total potential value could climb by several billion dollars. The terms represent a major, albeit heavily backloaded, bet on Genesis and its generative and predictive AI platform, GEMS. Chemists use the platform to create drug candidates, predict their properties, interrogate those predictions and decide what to synthesize, with AI agents orchestrating models that include Genesis’ 3D structure prediction technology, Pearl. Partnering with Incyte could further strengthen GEMS, with Genesis using its partner’s data in a secure manner to train its platform. The arrangement is one of the first major pharma-AI alliances designed to support large-scale foundation model training using a partner’s proprietary experimental data, the companies said. Incyte will also provide recurring research funding to Genesis to support AI model training and inference compute workloads. Genesis, a 2023 Fierce 15 honoree, raised $200 million in 2023 and inked a deal with Gilead Sciences in 2024. The activity has cemented Genesis’ status as a player in the rapidly emerging AI drug discovery space. News of the expanded Incyte deal came one day after the biotech partnered with Edison Scientific to deploy an AI scientist across its drug discovery and development operations. Bristol Myers Squibb added to the AI news flow Wednesday, unveiling an agreement with Anthropic to use Claude to accelerate drug discovery, development and delivery. Anthropic quoted representatives from Genmab, Novo Nordisk and Sanofi when it launched Claude for Life Sciences last year. Novo and Sanofi have also inked deals with Anthropic rival OpenAI, while Merck & Co. recently partnered with Google. The content above comes from the network. if any infringement, please contact us to modify.

As health tech gets more competitive, a strategy companies use to stand out is providing their products for free. They’re betting this will help build up a large and loyal base of users who will be willing to pay later once they grow accustomed to it. It’s a classic playbook used by companies such as OpenEvidence and OpenAI (and many, many companies across tech before them). The big question, though, is how to make money while it’s free. Health tech’s newest unicorn, Forus, says it found an answer that will keep it free for healthcare providers to use indefinitely. The New York City-based startup, which raised $160 million last week at a $1 billion valuation, automates the administrative steps to getting a prescription approved and filled. (Forus was formerly known as Tandem. ) When doctors use its platform to check their patients’ insurance coverage for different medications, Forus builds a map of which drug a patient was prescribed, the insurance plan they’re on, the pharmacy it routed to and whether coverage was denied or approved. Its system learns from this map to suggest more efficient paths to getting patients’ scripts approved in the future. But as the adage goes, if you’re not paying for the product, you’re the product. Access to that information is also valuable to pharma companies, which need it to understand where their drugs are reaching patients and where coverage is changing — and they’re willing to pay for it. “A lot of the challenge in pharma today is that they have a bunch of different companies selling them different subsets of data, and then they have to work through a combination of consulting firms and guessing to figure out what to do with that,” CEO and founder Sahir Jaggi told me. “The way we think of ourselves is that the network can actually help facilitate the right stuff on the ground.” In addition to business intelligence, pharma companies also pay to include their patient support programs on Forus’ platform for doctors to access after they choose a drug. “It’s unsustainable to have so many new things that all cost so much money even if they are reducing some of the administrative costs in the system,” Jaggi said of the many AI tools on the market. — Ngai (This is an edition of the Endpoints News Health Tech newsletter. Subscribe here to get it directly in your inbox.) HERE’S WHAT’S NEW Driven by GLP-1s, pharma’s relationship with consumers is starting to change Pharmaceutical companies’ ability to interact with the patients taking their medications has changed over the last few years.“Pharma has become so much more patient-centric in the last five years, and they’re doing things they never did in the past,” Eversana CEO Mark Thierer said. TrumpRx adds more than 600 generic meds, building on one success in US pricing Joined by executives from existing DTC-focused drug distribution companies, including Mark Cuban and officials from GoodRx and Amazon Pharmacy, the update to TrumpRx takes advantage of the generic marketplace, where the US fares better than other nations. THIS WEEK IN HEALTH TECH

Global biopharma company Bristol Myers Squibb announced a strategic agreement with AI safety and research company Anthropic to deploy Claude throughout its research, manufacturing, corporate, clinical development and commercial functions. Bristol said the deployment will focus on three areas of its business: implementing Claude Code within engineering and data science teams for AI and software development, embedding agents into workflows and connecting Claude to BMS's "institutional knowledge." The company's research teams will have access to Claude to aid in identifying and optimizing drug targets across oncology, neuroscience, hematology and immunology. Anthropic's AI will also be used within Bristol's drug-development processes, including automating trial documentation and regulatory submissions. Claude will also assist with manufacturing, "from root‑cause investigation and Corrective and Preventive Action documentation to data‑driven batch-release decisions," and with commercial and medical affairs, including engaging with healthcare professionals. Anthropic's AI will also be integrated into all of Bristol Myers Squibb's scientific, clinical, regulatory and commercial aspects to "activate that knowledge where and when it is most needed, with full enterprise governance and audit controls in place," the company said. "Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it," Greg Meyers, EVP and chief digital and technology officer at Bristol Myers Squibb, said in a statement. "Anthropic’s Claude gives us the agentic capabilities, pace of innovation and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them." THE LARGER TREND Numerous pharmaceutical and biopharma companies are partnering with large-scale AI companies to implement the technology across their organizations. Last month, OpenAI announced a partnership with Novo Nordisk , which would deploy OpenAI's capabilities across its global operations, from drug discovery to commercial functions, and upskill its workforce in AI literacy. OpenAI has also collaborated with Sanofi , Moderna and Thermo Fisher Scientific . Google DeepMind spinout Isomorphic Labs , which announced a $2.1 billion investment earlier this month, signed major drug-discovery partnerships with Novartis and Eli Lilly and Co. , focused on AI-enabled drug design. Last week, French company Owkin , which develops AI tools for drug discovery and pharmaceutical research, announced it entered into a three-year licensing agreement with AstraZeneca for the pharma giant to use K Pro, Owkin's AI Scientist platform designed for pharmaceutical research and decision support. HIMSS is hosting the one-day AI Executive Leadership Summit in Boston on June 24, 2026, followed by its AI in Healthcare Forum June 25-26. Register separately for the two events here and here .